 In China, products classically display a very different product lifecycle than in other countries.
This is primarily due to :
> Many of the older MNC brands have never had patent protection in China and hence have competed with generics over a
period of time.
> The traditionally poor quality of local generics – big base in China remains non GMP based.
> The hospital commercial model - not aligned to lowering the cost of drug treatment ie 50% of all hospital profit comes from the
sale of pharmaceuticals.
> The domestic companies promotional model – cash based with limited or no scientific promotion.
> Adopted a national selling and distribution model whilst domestic companies are regionally based – difficult to expand
nationally.
As a result, none of the top 10 selling Rx products are patent protected.
|
